Synthego Corp.

Plus Kaundinya named president and CEO at GlycoERA, and updates from Plexium, Alentis, ADCendo, Xcell and more

After spearheading Keytruda’s development, next challenge for the pharma CMO will come at Eikon; plus updates from Mammoth, OraSure, Strata and Acacia

Plus updates from Atara, Moderna, Regeneron, Agios, GSK, BioMarin, Bayer, Intellia-ONK, Merck KGaA, Blue Water

A burst of research is radically expanding tools to optimize CRISPR therapies and access new targets

Plus: Synthego, Hookipa, Nuevocor and more

Cellares’ walk-away cell manufacturing platform could go all the way from preclinical development to marketed product

A UCSF-led team has identified host pathways that could inform development of countermeasures against future coronaviruses, as they interact with multiple coronaviruses that recently made the

Menlo Ventures’ new fund signals that life sciences again a core focus for the firm

Synthego’s $100M financingSynthego Corp. raised $100 million in a series D round co-led by new investor Wellington Management and existing investors RA Capital and 8VC. Founders Fund, Menlo

Why there’s a gap in standards research for somatic cell versus germline editing